eNewsroom for: IP Shakti

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/IP Shakti/Screen Shot 2013-03-27 at 3.12.53 PM.png

IP Shakti Company Profile

IPShakti, LLC is an early stage fund for de-risking technologies by performing critical and essential proof of concept (POC). We already have capital commitments of over $30 Million for investing in cutting edge life science and biomedical technologies. Although life science research is thriving, many valuable technologies fail to make it to market. This is especially disheartening in medical fields, as patients anxiously await new technology to improve their quality of life. At IPShakti, we strive to make sure no valuable technology falls through the cracks. We support the early stage research with gap funding that most venture capital firms hesitate to fund because of small size or level of development. IPShakti advances technologies by selecting the right intellectual property assets, negotiating appropriate licenses, and creating other mechanisms for commercialization. Utilizing an open innovation model, IPShakti takes advantage of the currently available network of resources around the world to create just-in-time POC laboratories. The POC laboratories allow for strategic investment in incubators and prototypes, which will de-risk technologies as they progress towards market distribution. All of the steps for development are broken down into unit processes, creating efficiencies for getting most of the work done without significant capital investments. IPShakti is not just an early stage seed fund, we work with our partners to develop key technology and ensure it is successfully delivered to the market. IPShakti understands the hurdles university, non-profit and small entities face when developing new innovations. We endeavor to create strong relationships, form mutual goals, and ensure a smoother process at the time of investment. We take pride in our partnerships.

News from IP Shakti:

Pharmaceutical Patent Sale of First-in-Class Compounds to Treat Women's Health Needs

IP Shakti, LLC is the exclusive broker of patents for therapeutic compounds currently in clinical development
PRINCETON, N.J., Aug. 30, 2013 /PRNewswire/ – IP Shakti has partnered with a California pharmaceutical company to market patent assets corresponding to three new therapeutics to t…

IP Shakti Introduces PipeLinX™, Linking Business to Emerging Technologies

PRINCETON, N.J., July 2, 2013 /PRNewswire/ – IP Shakti, an early stage biomedical fund, has announced the launch of PipeLinX™, a new concept in open innovation solutions. The industry push toward externalization has grown in recent years, but sorting through the incoming volume of technol…

New Autism Detection System Commercialized through Partnership of IP Shakti, LLC and Shizuoka University

Advanced Eye Gaze Detection System poised to change future of Autism diagnosis
PRINCETON, N.J., March 28, 2013 /PRNewswire/ – IP Shakti, LLC is pleased to announce a partnership with Shizuoka University, of Hamamatsu, Japan, to commercialize a system for autism detection in young infants. A…

IP Shakti's CEO-In-Residence Program Welcomes First Round of New CEOs

CEOs-In-Residence programs represent worldwide initiative to provide start-ups with experienced management
PRINCETON, N.J., March 21, 2013 /PRNewswire/ – IP Shakti (www.ipshakti.com) has now launched a CEO-In-Residence (CIR) program with their existing gap fund and technology portf…